

genedrive plc
("genedrive" or the "Company")

Grant of Options

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that on 2 December 2021 share options ("Options") were granted to members of its senior management team to acquire a total of 400,000 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price of 31p being equal to the closing price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue and other financial targets, as well as completing certain strategic projects in the year ending 30 June 2024. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	<i>Details of the person discharging managerial responsibilities / person closely associated</i>	
<i>a.</i>	<i>Name</i>	1. Alex Mann 2. Jonathan Barber 3. Gino Miele 4. Colleen Phythian
2.	<i>Reason for the notification</i>	
<i>a.</i>	<i>Position/status</i>	1. Commercial Director 2. Operations Director 3. R&D Director 4. Director of Quality & Regulation
a.	<i>Initial notification /Amendment</i>	<i>Initial notification</i>
3.	<i>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</i>	
a.	<i>Name</i>	<i>genedrive plc</i>

b.	LEI	213800ZYODIRZ87Y4K14																		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted																			
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each GB00B1VKB244																		
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017																		
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th></th><th></th><th></th></tr> <tr> <th>PDMR</th><th>Exercise price</th><th>No of Options</th></tr> </thead> <tbody> <tr> <td>Alex Mann</td><td>31p</td><td>100,000</td></tr> <tr> <td>Jonathan Barber</td><td>31p</td><td>100,000</td></tr> <tr> <td>Gino Miele</td><td>31p</td><td>100,000</td></tr> <tr> <td>Colleen Phythian</td><td>31p</td><td>100,000</td></tr> </tbody> </table>				PDMR	Exercise price	No of Options	Alex Mann	31p	100,000	Jonathan Barber	31p	100,000	Gino Miele	31p	100,000	Colleen Phythian	31p	100,000
PDMR	Exercise price	No of Options																		
Alex Mann	31p	100,000																		
Jonathan Barber	31p	100,000																		
Gino Miele	31p	100,000																		
Colleen Phythian	31p	100,000																		
d.	Aggregated information Aggregated volume Price	N/A																		
e.	Date of the transaction	2021-12-02																		
f.	Place of the transaction	Outside a trading venue																		

For further details please contact:

genedrive plc

David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245

Peel Hunt LLP (Nominated Adviser and Joint Broker)

James Steel

+44 (0)20 7418 8900

finnCap (Joint Broker)

Geoff Nash / Kate Bannatyne / Alice Lane

+44 (0)20 7220 500

Walbrook PR Ltd (Media Relations & Investor Relations)

Paul McManus / Anna Dunphy

+44 (0)20 7933 8780

or genedrive@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7876
741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEANAAEDPFFEA